NCCN Clinical Practice Guidelines in Oncology: Hodgkin lymphoma, version 2.2020 Guidelines
| Authors: | Hoppe, R. T.; Advani, R. H.; Ai, W. Z.; Ambinder, R. F.; Armand, P.; Bello, C. M.; Benitez, C. M.; Bierman, P. J.; Boughan, K. M.; Dabaja, B.; Gordon, L. I.; Hernandez-Ilizaliturri, F. J.; Herrera, A. F.; Hochberg, E. P.; Huang, J.; Johnston, P. B.; Kaminski, M. S.; Kenkre, V. P.; Khan, N.; Lynch, R. C.; Maddocks, K.; McConathy, J.; McKinney, M.; Metzger, M.; Morgan, D.; Mulroney, C.; Rabinovitch, R.; Rosenspire, K. C.; Seropian, S.; Tao, R.; Winter, J. N.; Yahalom, J.; Burns, J. L.; Ogba, N. |
| Title: | NCCN Clinical Practice Guidelines in Oncology: Hodgkin lymphoma, version 2.2020 |
| Abstract: | The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. Current management of classic HL involves initial treatment with chemotherapy alone or combined modality therapy followed by restaging with PET/CT to assess treatment response. Overall, the introduction of less toxic and more effective regimens has significantly advanced HL cure rates. This portion of the NCCN Guidelines focuses on the management of classic HL. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 18 |
| Issue: | 6 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2020-06-01 |
| Start Page: | 755 |
| End Page: | 781 |
| Language: | English |
| DOI: | 10.6004/jnccn.2020.0026 |
| PUBMED: | 32502987 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2020 -- Source: Scopus |
